首页> 外文期刊>The Journal of biological chemistry >Specificity of Intersubunit General Anesthetic-binding Sites in the Transmembrane Domain of the Human α1β3γ2 γ-Aminobutyric Acid Type A (GABAA) Receptor
【24h】

Specificity of Intersubunit General Anesthetic-binding Sites in the Transmembrane Domain of the Human α1β3γ2 γ-Aminobutyric Acid Type A (GABAA) Receptor

机译:人α1β3γ2γ-氨基丁酸型(GABAA)受体的跨膜结构域中的跨性跨膜结构域中的梭津的一般麻醉结合位点的特异性

获取原文
           

摘要

GABA type A receptors (GABAAR), the brain's major inhibitory neurotransmitter receptors, are the targets for many general anesthetics, including volatile anesthetics, etomidate, propofol, and barbiturates. How such structurally diverse agents can act similarly as positive allosteric modulators of GABAARs remains unclear. Previously, photoreactive etomidate analogs identified two equivalent anesthetic-binding sites in the transmembrane domain at the β+-α? subunit interfaces, which also contain the GABA-binding sites in the extracellular domain. Here, we used R-[3H]5-allyl-1-methyl-5-(m-trifluoromethyl-diazirynylphenyl) barbituric acid (R-mTFD-MPAB), a potent stereospecific barbiturate anesthetic, to photolabel expressed human α1β3γ2 GABAARs. Protein microsequencing revealed that R-[3H]mTFD-MPAB did not photolabel the etomidate sites at the β+-α? subunit interfaces. Instead, it photolabeled sites at the α+-β? and γ+-β? subunit interfaces in the transmembrane domain. On the (+)-side, α1M3 was labeled at Ala-291 and Tyr-294 and γ2M3 at Ser-301, and on the (?)-side, β3M1 was labeled at Met-227. These residues, like those in the etomidate site, are located at subunit interfaces near the synaptic side of the transmembrane domain. The selectivity of R-etomidate for the β+-α? interface relative to the α+-β?/γ+-β? interfaces was >100-fold, whereas that of R-mTFD-MPAB for its sites was >50-fold. Each ligand could enhance photoincorporation of the other, demonstrating allosteric interactions between the sites. The structural heterogeneity of barbiturate, etomidate, and propofol derivatives is accommodated by varying selectivities for these two classes of sites. We hypothesize that binding at any of these homologous intersubunit sites is sufficient for anesthetic action and that this explains to some degree the puzzling structural heterogeneity of anesthetics.
机译:GABA型受体(GABAAR)是大脑的主要抑制性神经递质受体,是许多全身麻醉剂的目标,包括挥发性麻醉剂,依托咪酯,异丙酚和巴比妥酸盐。这种结构多样化的药剂如何与加巴尔斯的积极变构调制剂仍然不清楚。以前,光反应戊酸亚胺类似物在β+-α的跨膜结构域中鉴定了两个等同的麻醉结合位点?亚单位界面,其还含有细胞外结构域中的GABA结合位点。这里,我们使用R-[3H] 5-烯丙基-1-甲基-5-(M-三氟甲基 - 二氧基苯基苯基)巴比妥酸(R-MTFD-MPAB),有效的立体间氨基脲麻醉剂,以光致标签表达人α1β3γ2GABAARS。蛋白质微量序列显示,R-[3H] MTFD-MPAb未在β+-α处于乙状胺酸盐基位的情况下进行光致图?亚单位接口。相反,它在α+-β的光ollabeled网站?和γ+-β?跨膜结构域中的亚基接口。在(+)侧,在Ser-301的Ala-291和Tyr-294和γ2M3上标记α1M3,并在(α)侧,在Met-227处标记β3M1。类似于癸胺位点的这些残留物位于跨膜结构域的突触侧附近的亚基界面。 β+-α的R- entomidatide的选择性?接口相对于α+-β?/γ+-β?接口> 100倍,而R-MTFD-MPAB的其部位的界面为50倍。每个配体可以增强另一个配体,展示位点之间的变构相互作用。通过对这两类位点的不同选择性来容纳巴比妥磺酸酯,戊胺和异丙酚衍生物的结构异质性。我们假设任何这些同源间隙位点的结合足以进行麻醉作用,并且这解释了麻醉剂的令人困惑的结构异质性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号